Lumpectomy Patients are at Highest Risk for Opioid Overprescription: A Comparison Between Practice Patterns and OPEN National Guidelines.

Lumpectomy Patients are at Highest Risk for Opioid Overprescription: A Comparison Between Practice Patterns and OPEN National Guidelines.

Publication date: Jan 12, 2025

Nearly 25% of opioid-related deaths are from prescribed opioids, and the exacerbation of the opioid epidemic by the coronavirus disease 2019 (COVID-19) pandemic underscores the urgent need to address superfluous prescribing. Therefore, we sought to align local opioid prescribing practices with national guidelines in postoperative non-metastatic breast cancer patients. A single-institution analysis included non-metastatic breast surgery patients treated between April 2020 and July 2021. ‘Overprescription’ was defined as a discharge prescription quantity of oral morphine equivalents (OMEs) greater than the upper limit of the procedure-specific Michigan Opioid Prescribing Engagement Network (OPEN) recommendations. Univariable and multivariate analyses identified risk factors associated with opioid prescribing. Overall, 464 patients met the inclusion criteria: 280 patients underwent lumpectomy, and 184 patients underwent mastectomy. 52% of patients were overprescribed opioids, including 74% of lumpectomy patients (p

Concepts Keywords
Coronavirus Breast
July Comparison
Mastectomy Guidelines
Michigan Highest
Morphine Lumpectomy
Metastatic
National
Open
Opioid
Opioids
Overprescription
Practice
Prescribing
Risk
Underwent

Semantics

Type Source Name
disease MESH coronavirus disease 2019
disease MESH breast cancer
pathway KEGG Breast cancer
drug DRUGBANK Morphine
drug DRUGBANK Methionine

Original Article

(Visited 3 times, 1 visits today)